Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1107384 | 0.97 | LMNA (0.30) | — | |
| SCHEMBL10633893 | 0.93 | TDP1 (0.32) | CYP1A2 | |
| SCHEMBL4815804 | 0.91 | TSHR (0.36) | — | |
| SCHEMBL4817998 | 0.91 | TSHR (0.36) | — | |
| SCHEMBL4814410 | 0.91 | TSHR (0.36) | — | |
| SCHEMBL4805907 | 0.91 | TSHR (0.36) | — | |
| SCHEMBL10766944 | 0.90 | TSHR (0.33) | — | |
| SCHEMBL27490809 | 0.88 | TSHR (0.38) | — | |
| SCHEMBL16052548 | 0.88 | TSHR (0.38) | — | |
| SCHEMBL27505755 | 0.88 | TSHR (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505859-B2 | Process for producing polydienes | BRIDGESTONE CORPORATION (JP) | 2016-11-29 | — | — | US | disclosed |
| EP-2780381-B1 | PROCESS FOR PRODUCING POLYDIENES | BRIDGESTONE CORP (JP) | 2015-10-07 | — | — | EP | disclosed |
| US-20140303327-A1 | Process For Producing Polydienes | BRIDGESTONE CORPORATION (JP) | 2014-10-09 | — | — | US | disclosed |
| EP-2780381-A1 | PROCESS FOR PRODUCING POLYDIENES | Bridgestone Corporation (JP) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013075085-A1 | PROCESS FOR PRODUCING POLYDIENES | BRIDGESTONE CORPORATION (JP) | 2013-05-23 | — | — | WO | disclosed |
| US-8323839-B2 | rechargeable batteries having a negative electrode comprising a thin film of active material which can absorb and discharge lithium, deposited on current collectors, a positive electrode which can lithiate or delithiate and a sufur or phosphorus compound as an electrolyte; high energy density | SANYO ELECTRIC CO., LTD. (JP) | 2012-12-04 | — | — | US | disclosed |
| US-7411096-B2 | Process for producing optically active phosphorus heterocyclic dimer | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2008-08-12 | — | — | US | disclosed |
| US-20060211888-A1 | 2,2'-bis-(1-alkylphosphetanes); a primary alkyl or cycloalkyl phosphine is reacted with 1,3-dichloropropane, in the presence of n-butyllithium, and then reacted with boron trihydride, oxygen, or sulfur, dimerizing, removing the boron trihydride, oxygen, or sulfur; assymetric hydrogenation catalysts | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2006-09-21 | — | — | US | disclosed |
| EP-1650216-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE DIMER OF PHOSPHORUS HETEROCYCLE | NIPPON CHEMICAL INDUSTRIAL COMPANY LIMITED (JP) | 2006-04-26 | — | — | EP | disclosed |
| US-20060024587-A1 | Nonaqueous electrolyte solution for secondary battery and nonaqueous electrolyte secondary battery | SANYO ELECTRIC CO., LTD. (JP) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211888-A1 | 2,2'-bis-(1-alkylphosphetanes); a primary alkyl or cycloalkyl phosphine is reacted with 1,3-dichloropropane, in the presence of n-butyllithium, and then reacted with boron trihydride, oxygen, or sulfur, dimerizing, removing the boron trihydride, oxygen, or sulfur; assymetric hydrogenation catalysts | OSBP2, OXSR1, OCIAD2 | CYP1A2 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.